Recent studies have presented that the pathophysiological mechanism of VTE in lung cancer patients is mainly due to the direct activation of coagulation by malignant cells through producing tissue factor (TF), cancer procoagulant (CP), cytokines, and inflammatory factors [27]. This evidence concerns the gene CP and lung carcinoma.